Published in Int J Radiat Oncol Biol Phys on October 01, 2003
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys (2005) 2.08
HDR Brachytherapy in the Management of High-Risk Prostate Cancer. Adv Urol (2012) 1.45
Hypofractionation for prostate cancer. Cancer J (2009) 1.21
Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol (2008) 1.04
Hypofractionated external-beam radiotherapy for prostate cancer. Prostate Cancer (2013) 0.99
Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite. Br J Radiol (2012) 0.96
Comparison of the helical tomotherapy against the multileaf collimator-based intensity-modulated radiotherapy and 3D conformal radiation modalities in lung cancer radiotherapy. Br J Radiol (2010) 0.88
Evaluation of the effect of prostate volume change on tumor control probability in LDR brachytherapy. J Contemp Brachytherapy (2011) 0.84
Clinical implications in the use of the PBC algorithm versus the AAA by comparison of different NTCP models/parameters. Radiat Oncol (2013) 0.82
Modelling the interplay between hypoxia and proliferation in radiotherapy tumour response. Phys Med Biol (2013) 0.81
Can the two mechanisms of tumor cell killing by radiation be exploited for therapeutic gain? J Radiat Res (2013) 0.80
The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer. Radiat Oncol (2015) 0.78
On the need to compensate for edema-induced dose reductions in preplanned (131)Cs prostate brachytherapy. Int J Radiat Oncol Biol Phys (2007) 0.77
Validation of Perfusion Quantification with 3D Gradient Echo Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using a Blood Pool Contrast Agent in Skeletal Swine Muscle. PLoS One (2015) 0.77
The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers. Phys Med Biol (2011) 0.77
Modeling prostate cancer: in regards to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401). Int J Radiat Oncol Biol Phys (2005) 0.75
In regard to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401): Incorporating clinical measurements of hypoxia into tumor control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys (2004) 0.75
Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate CAncer (THEPCA) Patients and Its Effects on Toxicity and Quality of Life: Protocol of a Randomized Feasibility Trial. JMIR Res Protoc (2015) 0.75
Assessment of micronecrotic tumor tissue using dynamic contrast-enhanced magnetic resonance imaging. Phys Med (2017) 0.75
Alpha/beta (α/β) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol (2016) 0.75
Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells. Sci Rep (2016) 0.75
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst (2011) 5.79
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys (2005) 5.44
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78
Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst (2005) 4.51
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol (2003) 4.33
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys (2007) 3.24
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys (2010) 2.84
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2010) 2.69
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys (2006) 2.69
Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.60
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther (2007) 2.44
Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results. Int J Radiat Oncol Biol Phys (2011) 2.23
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys (2005) 2.08
Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol (2005) 2.04
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy (2012) 2.03
ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung. Int J Radiat Oncol Biol Phys (2010) 2.00
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98
The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol (2010) 1.87
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys (2005) 1.83
Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.69
Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther (2008) 1.67
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys (2003) 1.65
Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study. Cancer (2007) 1.64
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys (2006) 1.62
Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery. Cancer (2007) 1.61
Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.61
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys (2005) 1.57
Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.55
Increased recurrences using intensity-modulated radiation therapy in the postoperative setting. Am J Clin Oncol (2010) 1.52
Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys (2002) 1.46
Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann Behav Med (2003) 1.45
Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns (2002) 1.44
Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther (2007) 1.43
Radiation pulmonary toxicity: from mechanisms to management. Semin Radiat Oncol (2010) 1.43
Why external beam radiotherapy is treatment of choice for most men with early-stage nonmetastatic prostate cancer. Urology (2008) 1.41
ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lung cancer. Am J Clin Oncol (2015) 1.39
The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Can J Urol (2017) 1.39
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer (2004) 1.38
Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology (2002) 1.37
Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging (2003) 1.34
Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis (2006) 1.33
Does treatment duration affect outcome after radiotherapy for prostate cancer? Int J Radiat Oncol Biol Phys (2008) 1.30
Dose delivered from Varian's CBCT to patients receiving IMRT for prostate cancer. Phys Med Biol (2007) 1.29
Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol (2007) 1.27
Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys (2006) 1.27
Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol (2004) 1.26
Pain control by image-guided radiosurgery for solitary spinal metastasis. J Pain Symptom Manage (2008) 1.25
Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys (2013) 1.24
A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys (2007) 1.23
Combining scatter reduction and correction to improve image quality in cone-beam computed tomography (CBCT). Med Phys (2010) 1.23
The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys (2003) 1.20
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer (2007) 1.18
Characteristics of cancer patients entering a smoking cessation program and correlates of quit motivation: implications for the development of tobacco control programs for cancer patients. Psychooncology (2004) 1.17
Prostate cancer gene therapy clinical trials. Mol Ther (2007) 1.17
A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.16
A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys (2008) 1.16
Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther (2011) 1.14
Measurement of intrafractional prostate motion using magnetic resonance imaging. Int J Radiat Oncol Biol Phys (2002) 1.13
Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.12
A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients. Ann Behav Med (2005) 1.12
Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol (2012) 1.11
2D/3D image fusion for accurate target localization and evaluation of a mask based stereotactic system in fractionated stereotactic radiotherapy of cranial lesions. Med Phys (2006) 1.11
Impact of marital status on survival among women with invasive cervical cancer: analysis of population-based surveillance, epidemiology, and end results data. J Low Genit Tract Dis (2010) 1.09
Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys (2005) 1.09
Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis. Neurosurgery (2012) 1.07
Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol (2008) 1.07
A technique of quantitatively monitoring both respiratory and nonrespiratory motion in patients using external body markers. Med Phys (2007) 1.07
Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. J Clin Oncol (2006) 1.07
In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res (2007) 1.06
Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol (2003) 1.06
Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys (2009) 1.06
Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther (2007) 1.06
Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.05
A finite element method to correct deformable image registration errors in low-contrast regions. Phys Med Biol (2012) 1.05
Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination. Urology (2003) 1.04
The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet (2009) 1.03
Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.01
A technique of using gated-CT images to determine internal target volume (ITV) for fractionated stereotactic lung radiotherapy. Radiother Oncol (2006) 1.01
Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys (2005) 1.00
Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. Clin Lung Cancer (2011) 0.99
Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer (2007) 0.99
Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14. J Palliat Med (2008) 0.98
Dosimetric verification and clinical evaluation of a new commercially available Monte Carlo-based dose algorithm for application in stereotactic body radiation therapy (SBRT) treatment planning. Phys Med Biol (2010) 0.98
A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate. Int J Radiat Oncol Biol Phys (2003) 0.98
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer (2005) 0.97
Evaluation of multiple image-based modalities for image-guided radiation therapy (IGRT) of prostate carcinoma: a prospective study. Med Phys (2013) 0.97